Dear Director, Laboratory Medicine Specialist, or Clinical Chemist/Biochemist,
The IFCC and ISOBM Working Group on Tumor Marker Harmonization is currently investigating opportunities to improve the harmonization of tumor marker testing, with a particular focus on carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3).
While full technical harmonization of patient results across platforms remains a challenge, we believe that standardized reporting — particularly clear identification of the test or measurement procedure used — plays an important role in ensuring appropriate interpretation and use of tumor marker results.
To better understand current global practices, we are conducting a brief survey targeting clinical laboratories worldwide. The questionnaire addresses routine practices in tumor marker use and reporting, and also includes specific questions related to PSA testing.
Our goal is to evaluate current practices, identify challenges faced by laboratories, and potentially develop guidance to support best practices in this area.
We would be grateful if you, or a colleague responsible for tumor marker testing, could complete the survey.
Thank you in advance for your valuable contribution to this important initiative.
On behalf of the IFCC WG-TMH & ISOBM WG-TMH,
Yours sincerely,
Huub van Rossum, PhD EuSpLM
(chair IFCC WG-TMH & ISOBM WG-TMH)
